Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Who May Qualify: - Ages 14-65 years, inclusive, at the time of consent - Pathogenic or likely pathogenic PKP2 gene mutation - Diagnosed with ARVC and meet 2010 Modified Task Force Criteria for ARVC as affected. - Functioning ICD Who Should NOT Join This Trial: - Currently receiving systemic immunosuppressive therapy, cytotoxic chemotherapy, immunoglobulin therapy or monoclonal antibody therapy - History of clinically significant liver disease, hepatitis B virus, hepatitis C virus, human weakened immune system virus, or tuberculosis infection - Previously dosed with any investigational or approved gene therapy product at any time - Concurrent participation in another interventional clinical trial unless approved by the Sponsor. Participation in a noninterventional study may be allowed at the investigator's discretion. - History of cardiac transplant. Always talk to your doctor about whether this trial is right for you.